文献速递特殊人群用药药物不良反应与药物警戒

母婴与儿科精准治疗知识门户(MPRINT-KP):母婴与儿科药理学研究格局分析

Maternal and Pediatric Precision in Therapeutic Knowledge Portal (MPRINT-KP): Landscape Analysis of Pharmacology Research in Maternal and Pediatric Patient Populations.
PubMed 文献 · Pharmacotherapy · 2026-01-01

MPRINT-KP 基于 BioBERT 模型构建,收录截至 2025 年 4 月 1 日的 758,560 篇母婴与儿科临床药理学研究论文,分类 F1 值 > 0.91。格局分析显示产后女性、孕妇、0–12 岁及 12–18 岁儿科患者的药理学知识缺口分别为 51.37%、32.47%、25.82%、32.11%,并利用 FAERS 与 MarketScan 数据发现多种药物相关的新不良事件信号。

要点

  • 产后女性药理学知识缺口最高(51.37%),其次为孕妇(32.47%)和 12–18 岁儿科患者(32.11%)。
  • 0–12 岁儿科患者知识缺口为 25.82%,大量药物缺乏药动学、药物流行病学或临床试验证据。
  • 在儿科发现 crisaborole 相关出血和莫西沙星相关心脏毒性等新不良事件信号。

核心结论

  • 首次对母婴与儿科人群的药理学知识缺口进行大规模格局分析,并利用真实世界数据发现新的药物相关不良事件证据。

研究设计与样本

  • 基于 BioBERT 模型构建 MPRINT-KP Silver,从 PubMed 分类药动学、药物流行病学和临床试验论文,F1 值 > 0.91。
  • 截至 2025 年 4 月 1 日,门户收录 758,560 篇母婴与儿科临床药理学研究论文。
  • 利用美国 FDA 不良事件报告系统(FAERS)和 MarketScan 理赔数据对证据有限的高处方药物进行药物警戒分析。

主要发现

  • 药理学知识缺口最高的人群为产后女性(51.37%)、孕妇(32.47%)、0–12 岁儿科患者(25.82%)和 12–18 岁儿科患者(32.11%)。
  • 儿科患者中新发现 crisaborole 相关出血和莫西沙星相关心脏毒性。
  • 孕妇中新发现特康唑相关心跳异常、苯佐那酯相关抑郁和焦虑障碍、丁螺环酮相关心跳异常、环苯扎林相关肾小管间质性肾炎、泮托拉唑相关听力损失及声音与共鸣障碍。

临床怎么用

  • 临床药师可借助 MPRINT-KP 识别母婴与儿科人群中药理学证据薄弱的药物,辅助用药决策。
  • 对产后女性、孕妇及 0–18 岁儿科患者使用证据有限的药物时,应关注药物警戒分析提示的新不良事件信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pregnant women and children have been underrepresented in clinical studies due to ethical concerns and perceived vulnerabilities. This resulted in a significant gap in knowledge regarding the safety and efficacy of medications for these populations. Maternal and Pediatric PRecision In Therapeutics Knowledge Portal (MPRINT-KP) is designed to provide a comprehensive view of pharmacokinetic, pharmaco-epidemiology, and clinical trial research evidence in maternal and pediatric patient populations. MPRINT-KP Silver was generated upon BioBERT models, due to their supreme performance in classifying pharmacokinetic, pharmaco-epidemiology, and clinical trial papers from PubMed, with an F1-score > 0.91. As of April 1, 2025, MPRINT-KP Silver contains 758,560 clinical pharmacology research papers in maternal and pediatric populations. The landscape analysis revealed a large number of drugs with pharmacology knowledge gaps, which is calculated as the relative frequency of drugs with no or weak (i.e., less than five publications) evidence in each of pharmacokinetic, pharmaco-epidemiology, or clinical trial study type. The highest pharmacotherapy knowledge gaps are in postpartum women, pregnant women, and pediatric patients between 0-12 and 12-18 years of age (51.37%, 32.47%, 25.82%, 32.11%, respectively). Pharmacovigilance analyses were conducted on highly prescribed drugs with limited pharmacology evidence in pediatric patients 0-2 year old and pregnant women using United States Food and Drug Administration Adverse Event Reporting System (FAERS) and MarketScan claims data. A number of new drug-associated adverse drug events (ADEs) were discovered. In pediatric patients, there were crisaborole-associated hemorrhage and moxifloxacin-associated cardiac toxicities. In pregnant women, the analysis revealed terconazole-associated abnormalities of heartbeat; benzonatate-associated depressive and anxiety disorders; buspirone-associated abnormalities of heartbeat; cyclobenzaprine-associated tubulo-interstitial nephritis; and pantoprazole-associated hearing loss and voice and resonance disorders. For the first time, a large-scale landscape analysis of pharmacotherapy knowledge gap in both maternal and pediatric patient populations was conducted and identified new drug associated ADE evidence using real world data.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Liu X, Shendre A, Wang L, et al. Maternal and Pediatric Precision in Therapeutic Knowledge Portal (MPRINT-KP): Landscape Analysis of Pharmacology Research in Maternal and Pediatric Patient Populations. Pharmacotherapy. 2026. PMID: 41730795. doi:10.1002/phar.70096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。